Avanos Medical (NYSE:AVNS) Upgraded at StockNews.com

Avanos Medical (NYSE:AVNS) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Wednesday.

Avanos Medical Price Performance

NYSE:AVNS opened at $14.74 on Wednesday. Avanos Medical has a one year low of $14.25 and a one year high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The stock has a market cap of $677.85 million, a PE ratio of 43.34 and a beta of 1.17. The stock has a 50 day moving average price of $15.84 and a 200 day moving average price of $18.79.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The firm had revenue of $179.60 million during the quarter, compared to analysts’ expectations of $177.23 million. Equities research analysts expect that Avanos Medical will post 1.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares in the company, valued at $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.94% of the stock is owned by insiders.

Institutional Investors Weigh In On Avanos Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in Avanos Medical in the third quarter valued at $42,000. Quantbot Technologies LP purchased a new stake in shares of Avanos Medical in the 4th quarter valued at $64,000. KBC Group NV raised its holdings in shares of Avanos Medical by 63.0% in the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock valued at $68,000 after buying an additional 1,095 shares during the period. State of Wyoming raised its holdings in shares of Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after buying an additional 2,923 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Avanos Medical by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock valued at $129,000 after buying an additional 6,714 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.